Purpose: To determine if treatment with motesanib AMG 706 in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in patients with advanced NSCLC (non-small cell lung cancer).
Inclusion Criteria:
Exclusion Criteria: